The advanced glycation end product-lowering agent ALT-711 Is a Low-Affinity inhibitor of thiamine Diphosphokinase

Rejuvenation Research

Volumn 14, Issue 4, 2011, Pages 383-391

  Krautwald, Martina ^b   Leech, Dale ^b   Horne, Stacey ^a   Steele, Megan L ^d   Forbes, Josephine ^a   Rahmadi, Anton ^c   Griffith, Renate ^a   Münch, Gerald ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; THIAMINE; THIAMINE PYROPHOSPHOKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; NONHUMAN; PRIORITY JOURNAL; VITAMIN METABOLISM;

ANIMALS; BINDING SITES; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ASSAYS; GLYCOSYLATION END PRODUCTS, ADVANCED; INHIBITORY CONCENTRATION 50; KIDNEY; KINETICS; MODELS, MOLECULAR; NUCLEOSIDE-DIPHOSPHATE KINASE; PROTEIN KINASE INHIBITORS; THIAMINE; THIAMINE PYROPHOSPHATE; THIAZOLES;

EID: 80051959176     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2010.1143     Document Type: Article

References (36)

1. Munch G, Schicktanz D, Behme A, Gerlach M, Riederer P, Palm D, Schinzel R. Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat Biotechnol 1999;17:1006-1010. (Pubitemid 29474858)
2. Mü nch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev 1997;23:134-143. (Pubitemid 27090752)
3. Sell DR, Kleinman NR, Monnier VM. Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice. FASEB J 2000;14:145-156. (Pubitemid 30051532)
4. Nagaraj RH, Monnier VM. Isolation and characterization of a blue fluorophore from human eye lens crystallins: In vitro formation from Maillard reaction with ascorbate and ribose. Biochim Biophys Acta 1992;1116:34-42.
5. Shamsi FA, Sharkey E, Creighton D, Nagaraj RH. Maillard reactions in lens proteins: Methylglyoxal-mediated modifications in the rat lens. Exp Eye Res 2000;70:369-380. (Pubitemid 30658907)
6. Vishwanath V, Frank KE, Elmets CA, Dauchot PJ, Monnier VM. Glycation of skin collagen in type I diabetes mellitus. Correlation with long-term complications. Diabetes 1986;35:916-921. (Pubitemid 16014445)
7. Wong A, Luth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T, Mü nch G. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res 2001;920:32-40. (Pubitemid 33086777)
8. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-1252. (Pubitemid 23273898)
9. Thornalley PJ. Glycation in diabetic neuropathy: Characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002;50:37-57.
10. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994;37:32-35.
11. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 1996;50:627-634. (Pubitemid 26274394)
12. Sugiyama T, Miyamoto K, Katagiri S. Fetal toxicity of aminoguanidine in mice and rats. J Toxicol Sci 1986;11:189-195.
13. Susic D. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem Soc Trans 2007;35:853-856. (Pubitemid 350206381)
14. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003;17: 1762-1764.
15. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813-1823. (Pubitemid 38857040)
16. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P, Cerami A, Brines M, Regan TJ. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 2000;97:2809-2813. (Pubitemid 30159253)
17. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001;104:1464-1470. (Pubitemid 32917336)
18. Mitsuda H, Takii Y, Iwami K, Yasumoto K. Purification and properties of thiamine pyrophosphokinase from parsely leaf. J Nutr Sci Vitaminol (Tokyo) 1975;21:103-115.
19. Voskoboev AI, Chernikevich IP. [Interaction of thiamine pyrophosphokinase from brewer's yeast with thiamine and adenosine-5'-triphosphate]. Biokhimiia 1977;42:79-84. (Pubitemid 8019593)
20. Peterson JW, Gubler CJ, Kuby SA. Partial purification and properties of thiamine pyrophosphokinase from pig brain. Biochim Biophys Acta 1975;397:377-394.
21. Angelides KJ, Hammes GG. Mechanism of action of the pyruvate dehydrogenase multienzyme complex from Escherichia coli. Proc Natl Acad Sci USA 1978;75:4877-4880. (Pubitemid 9056302)
22. McCool BA, Plonk SG, Martin PR, Singleton CK. Cloning of human transketolase cDNAs and comparison of the nucleotide sequence of the coding region in Wernicke-Korsakoff and non-Wernicke-Korsakoff individuals. J Biol Chem 1993; 268:1397-1404. (Pubitemid 23019790)
23. Butterworth RF. Effects of thiamine deficiency on brain metabolism: Implications for the pathogenesis of the Wernicke-Korsakoff syndrome. Alcohol Alcohol 1989;24: 271-279. (Pubitemid 19226143)
24. Thornalley PJ, Hooper NI, Jennings PE, Florkowski CM, Jones AF, Lunec J, Barnett AH. The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Res Clin Pract 1989;7:115-120. (Pubitemid 19221706)
25. Bettendorff L, Mastrogiacomo F, Kish SJ, Grisar T. Thiamine, thiamine phosphates, and their metabolizing enzymes in human brain. J Neurochem 1996;66:250-258. (Pubitemid 26010788)
26. Pinto E, Pedersen M, Snoeijs P, Van Nieuwerburgh L, Colepicolo P. Simultaneous detection of thiamine and its phosphate esters from microalgae by HPLC. Biochem Biophys Res Commun 2002;291:344-348. (Pubitemid 34694410)
27. Timm DE, Liu J, Baker LJ, Harris RA. Crystal structure of thiamin pyrophosphokinase. J Mol Biol 2001;310:195-204. (Pubitemid 32619962)
28. Artsukevich IM, Voskoboev AI, Ostrovskii Iu M. [Purification and several properties of thiamine pyrophosphokinase from rat liver]. Vopr Med Khim 1977;23:203-210. (Pubitemid 8079874)
29. Sanioto SM, Reinauer H, Hollmann S. Thiamine pyrophosphokinase activity in liver, heart and brain crude extracts of control and thiamine deficient rats. Int J Vitam Nutr Res 1977;47:315-324.
30. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
31. Nobecourt E, Zeng J, Davies MJ, Brown BE, Yadav S, Barter PJ, Rye KA. Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the nonenzymatic glycation of apolipoprotein A-I. Diabetologia 2008;51:1008-1017.
32. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo.Nature 1996;382:275-278. (Pubitemid 26251366)
33. Thornalley PJ, Minhas HS. Rapid hydrolysis and slow alpha, beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem Pharmacol 1999;57:303-307. (Pubitemid 29056208)
34. Yang S, Litchfield JE, Baynes JW. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys 2003;412:42-46. (Pubitemid 36324363)
35. Ferguson GP, VanPatten S, Bucala R, Al-Abed Y. Detoxification of methylglyoxal by the nucleophilic bidentate, phenylacylthiazolium bromide. Chem Res Toxicol 1999;12: 617-622. (Pubitemid 29354744)
36. Forbes JM, Thallas-Bonke V, Cooper ME, Thomas MC. Advanced glycation: How are we progressing to combat this web of sugar anomalies in diabetic nephropathy. Curr Pharm Des 2004;10:3361-3372. (Pubitemid 39276622)